Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
‘All travellers arriving in Britain will face mandatory tests.
The Times has also learnt that workplace testing for coronavirus will be increased next week under plans to identify infected people who are not showing symptoms.
At present people travelling to Britain are required to provide proof of a negative coronavirus test.
Under the new regime, to be implemented on February 15, people will be required to take PCR swab tests for the virus on days two and eight of their ten-day quarantine.’ Source The Times
SNG001 is a formulation of recombinant interferon beta for inhaled delivery by nebuliser that is in development for the treatment of virus-induced lower respiratory tract illnesses.
Patients who received SNG001 had greater odds of improvement and recovered more rapidly from SARS-CoV-2 infection than patients who received placebo, providing a strong rationale for further trials.
SNG001 has been shown to boost lung antiviral defences, as assessed by sputum cell antiviral biomarkers, in patients with and without respiratory viral infections.
SNG001, a treatment already studied and shown to be well tolerated in patients with asthma and COPD, seems to also be well tolerated in patients admitted to hospital with COVID-19, with a range of clinical outcomes displaying a beneficial pattern of response to SNG001 therapy.
The odds of improvement on the OSCI scale were more than two-fold greater in the SNG001 group than in the placebo group on day 15 or 16 and more than three-fold greater on day 28.
Further trials in different clinical settings, including in ventilated patients or in patients with mild to moderate COVID-19 not requiring treatment in hospital, are underway.
With the second wave of COVID-19 coinciding with the winter incidence of cold and influenza in the northern hemisphere, the development of broad-spectrum antiviral agents, such as interferon-ß, that boost local lung defences rather than targeting specific viral mechanisms, might carry substantial additional benefits to patients and to overburdened health-care systems.
Source The Lancet
Revenue is forecast to grow 21.8% per year
https://simplywall.st/stocks/gb/pharmaceuticals-biotech/aim-dddd/4d-pharma-shares
Flying soon?
Trading at 48.8% below estimate
With prediction of earnings growth of 70.2% per year
https://simplywall.st/stocks/gb/pharmaceuticals-biotech/lse-oxb/oxford-biomedica-shares
SP prediction for Monday?